Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

4 terminated/withdrawn out of 22 trials

Success Rate

73.3%

-13.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

64%

7 of 11 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2
12(57.1%)
N/A
9(42.9%)
21Total
Phase 2(12)
N/A(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT05321342Not ApplicableCompleted

Coaching Teachers in Bullying Detection and Intervention

Role: collaborator

NCT05585918Not ApplicableActive Not Recruiting

The R-CITY Project: A Collaborative Intervention With Teachers and Youth

Role: collaborator

NCT05220410Phase 2Completed

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Role: lead

NCT04367506Not ApplicableCompleted

Pilot Testing a Digital Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness

Role: collaborator

NCT04433858Phase 2Active Not Recruiting

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Role: lead

NCT04226898Phase 2Unknown

Synbiotic Compound to Reduce Symptoms of Schizophrenia

Role: lead

NCT03349528Phase 2Unknown

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

Role: lead

NCT04433845Phase 2Unknown

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Role: lead

NCT05541302Completed

Retrospective TMS Therapy for Adults With MDD

Role: collaborator

NCT02640950Not ApplicableCompleted

An Open Label Trial of TMS Therapy for Bipolar Depression

Role: lead

NCT02810964Phase 2Completed

Sulforaphane to Reduce Symptoms of Schizophrenia

Role: lead

NCT03883360Phase 2Withdrawn

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

Role: collaborator

NCT04340102Not ApplicableWithdrawn

Development of a Scalable Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness

Role: collaborator

NCT01242371Not ApplicableCompleted

Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia

Role: lead

NCT02008773Phase 2Completed

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

Role: collaborator

NCT01731171Not ApplicableCompleted

Probiotics to Prevent Relapse After Hospitalization for Mania

Role: lead

NCT02234752Phase 2Terminated

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

Role: lead

NCT03273062Phase 2Unknown

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

Role: lead

NCT01944657Not ApplicableWithdrawn

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

Role: lead

NCT02652598Phase 2Unknown

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

Role: lead